HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
-2.55%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.3B
AUM Growth
+$2.3B
(-5.6%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-4.55%
Top 10 Holdings %
Top 10 Hldgs %
49.1%
Holding
90
New
20
Increased
22
Reduced
16
Closed
17
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$125M |
| 2 |
Cencora
COR
|
$75.5M |
| 3 |
Centene
CNC
|
$61.2M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$60M |
| 5 |
McKesson
MCK
|
$56.2M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$106M |
| 2 |
Humana
HUM
|
$106M |
| 3 |
Danaher
DHR
|
$103M |
| 4 |
CVS Health
CVS
|
$92.8M |
| 5 |
Thermo Fisher Scientific
TMO
|
$92.3M |
Sector Composition
| 1 | Healthcare | 89.61% |
| 2 | Consumer Discretionary | 4.54% |
| 3 | Real Estate | 3.95% |
| 4 | Financials | 1.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $212M | 9.15% | 3,584,160 +2,109,790 | +143% | +$125M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $140M | 6.04% | 1,278,228 +43,180 | +3% | +$4.73M |
|
3
Biogen
BIIB
$19.4B
| $132M | 5.7% | 466,830 +127,530 | +38% | +$36.1M |
|
|
4
Cencora
COR
$56.5B
| $107M | 4.62% | 896,680 +632,340 | +239% | +$75.5M |
|
5
Petco
WOOF
$1.12B
| $104M | 4.5% | 4,944,450 | – | – |
|
6
Natera
NTRA
$23.1B
| $100M | 4.32% | 897,646 +107,988 | +14% | +$12M |
|
7
Envista
NVST
$3.52B
| $94.1M | 4.06% | 2,249,972 +1,084,112 | +93% | +$45.3M |
|
|
8
McKesson
MCK
$85.4B
| $88.2M | 3.81% | 442,470 +281,710 | +175% | +$56.2M |
|
9
Medtronic
MDT
$119B
| $76.8M | 3.31% | 612,480 +11,760 | +2% | +$1.47M |
|
10
Boston Scientific
BSX
$156B
| $74.1M | 3.2% | 1,707,681 +497,111 | +41% | +$21.6M |
|
11
Tenet Healthcare
THC
$16.3B
| $72M | 3.11% | 1,084,240 +708,060 | +188% | +$47M |
|
|
NVRO
12
DELISTED
NEVRO CORP.
NVRO
| $61.6M | 2.66% | 529,230 +152,900 | +41% | +$17.8M |
|
|
13
Centene
CNC
$14.3B
| $61.2M | 2.64% | +982,630 | New | +$61.2M |
|
|
14
Jazz Pharmaceuticals
JAZZ
$7.75B
| $60M | 2.59% | +460,790 | New | +$60M |
|
15
Stryker
SYK
$150B
| $58.7M | 2.53% | 222,510 -50,680 | -19% | -$13.4M |
|
16
HCA Healthcare
HCA
$94.5B
| $57.6M | 2.49% | 237,360 +67,650 | +40% | +$16.4M |
|
17
BioCryst Pharmaceuticals
BCRX
$1.74B
| $55.3M | 2.39% | 3,849,470 +601,370 | +19% | +$8.64M |
|
18
LivaNova
LIVN
$3.08B
| $51.6M | 2.23% | 652,150 +527,150 | +422% | +$41.7M |
|
19
Welltower
WELL
$113B
| $50.9M | 2.2% | 617,480 +182,890 | +42% | +$15.1M |
|
20
Zimmer Biomet
ZBH
$21B
| $48.4M | 2.09% | 330,590 -433,740 | -57% | -$63.5M |
|
21
Universal Health Services
UHS
$11.6B
| $48.2M | 2.08% | 348,680 +23,103 | +7% | +$3.2M |
|
22
Neurocrine Biosciences
NBIX
$13.8B
| $42.8M | 1.84% | 445,739 +55,759 | +14% | +$5.35M |
|
23
Cigna
CI
$80.3B
| $42.4M | 1.83% | +211,780 | New | +$42.4M |
|
24
Ventas
VTR
$30.9B
| $40M | 1.73% | 725,010 +235,370 | +48% | +$13M |
|
|
CANO
25
DELISTED
Cano Health, Inc.
CANO
| $34.9M | 1.51% | +2,754,730 | New | +$34.9M |
|